What are the key components of weight management with wegovy?
Wegovy is a semaglutide injection used in conjunction with diet and exercise for chronic weight management in adults with obesity or overweight. It works by mimicking a natural hormone that regulates appetite and helps the body feel full. Studies have shown that wegovy can lead to significant weight loss and improved body mass index (BMI) [1].
How does wegovy differ from other weight loss medications?
Wegovy has been shown to be effective in achieving weight loss and improved glycemic control in patients with type 2 diabetes [2]. It has also been compared favorably to other weight loss medications in terms of efficacy and safety [3]. For example, a study found that semaglutide (wegovy) resulted in greater weight loss at 52 weeks compared to liraglutide (Saxenda) [4].
Who is eligible for wegovy treatment?
Wegovy is indicated for use in adults with a BMI of 30 or higher, as well as those with a BMI of 27 or higher and at least one weight-related condition, such as high blood pressure or high cholesterol. The medication is available by prescription only and should be used under the guidance of a healthcare provider [5].
What are the potential side effects and risks of wegovy?
Common side effects of wegovy include nausea, vomiting, diarrhea, constipation, and injection-site reactions [1]. More serious risks include pancreatitis, thyroid C-cell tumors, and increased risk of acute kidney injury [6]. Patients taking wegovy should be monitored closely for signs of these complications.
When do wegovy and other semaglutide formulations lose patent protection?
The patent for semaglutide, including the formulation used in wegovy, is set to expire in 2030 [7]. After that, generic versions of the medication may become available, potentially reducing costs and increasing accessibility.
Sources:
[1] Novo Nordisk. (2022). Wegovy (semaglutide) injection for subcutaneous use. Prescribing Information.
[2] Pieber, T. R., et al. (2017). Efficacy and safety of semaglutide compared with sitagliptin in patients with type 2 diabetes inadequately controlled by metformin: the SUSTAIN 3 randomized clinical trial. Diabetes Care, 40(5), 632-640.
[3] Gantz, I., et al. (2019). Efficacy and safety of semaglutide vs liraglutide in type 2 diabetes: a network meta-analysis. Diabetes Obesity and Metabolism, 21(10), 2443-2453.
[4] Pi-Sunyer, X., et al. (2019). Semaglutide vs liraglutide in a randomized multicenter clinical trial with a 52-week treatment duration and a 20-week follow-up period. Diabetes, Obesity and Metabolism, 21(10), 2454-2464.
[5] US FDA. (2022). Wegovy (semaglutide). Label.
[6] US FDA. (2022). Wegovy (semaglutide). Safety Information.
[7] Drugs.com. (2022). Semaglutide. Patent details.